—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Tubize-Fin (TUB.BR) — the peer cohort

As of 2026-09-25 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Tubize-Fin ranks 7 of 7 in its cohort on the Closelooknet composite (25/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
TUB.BR Tubize-Fin 25 15 17 25 warn 27.5%
HALO Halozyme Therapeutics Inc 74 95 94 46 ok 2.5%
BION.SW BB Biotech AG 73 66 96 81 info 10.4%
ARGX.BR Argen-X 64 74 74 29 ok 8.6%
ARGX argenx NV ADR 64 74 73 29 ok 10.6%
ONC BeiGene, Ltd. 64 79 62 32 ok 6.3%
KRYS Krystal Biotech Inc 61 68 85 19 ok 9.6%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-25

Quick answers

Who are Tubize-Fin's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BB Biotech AG (BION.SW), Argen-X (ARGX.BR), argenx NV ADR (ARGX), BeiGene, Ltd. (ONC), Krystal Biotech Inc (KRYS).

How does TUB.BR score against its peers?

Tubize-Fin's composite reads 25/100, ranking 7 of 7 in its cohort as of 2026-09-25; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.